Further analysis of surface levels of the proteins revealed significantly reduced expression of CTLA-4 in intermediate prognosis AML patients when compared to the favourable (p = 0.0348) or adverse (p = 0.0227) group (Figure 3A,B). Here, CTLA4 is linked to acute myeloid leukemia.